Avaxia Biologics Receives $6,400,000 Series B Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b0f29c8c-a5cd-4681-8125-7c77fb781c6e&Preview=1 -
Date
12/18/2012 -
Company Name
Avaxia Biologics -
Mailing Address
128 Spring Street Lexington, MA 02421 -
Company Description
Avaxia is developing oral antibody products for diseases and disease targets that can be reached through the mouth and the gastrointestinal tract. -
Website
http://www.avaxiabiologics.com -
Transaction Type
Venture Equity -
Transaction Amount
$6,400,000 -
Transaction Round
Series B -
Proceeds Purposes
Avaxia plans to use the proceeds to fund a first-in-human Phase 1b clinical trial of its oral anti-TNF antibody, AVX-470, for the treatment of ulcerative colitis. -
M&A Terms
-
Venture Investor
Cherrystone Angel Group -
Venture Investor
Golden Seeds -
Venture Investor
Beacon Angels -
Venture Investor
Boston Harbor Angels -
Venture Investor
Launchpad Venture Group -
Venture Investor
Beta Fund -
Venture Investor
Granite State Angels -
Venture Investor
Maine Angels -
Venture Investor
Keiretsu Forum – Boston/New England
